Balanced news tone
News Sentiment
CCCC sentiment intelligence
C4 Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
54 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-5.6% over one week, +4.1% over four weeks, trend active, and near fair-value range.
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
-5.6%
Price reacting lower
Trend fit
Trend active
4.1% over four weeks
Fair value
8.4%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
37
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 13:40
- Source
- Market source
StockStory
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
Stock Titan
Direct company coverage
C4 Therapeutics (NASDAQ: CCCC) CMO gains shares via RSU vesting, withholds some for taxes
C4 Therapeutics' Chief Medical Officer, Leonard Reyno, acquired 15,325 shares of common stock on July 10, 2026, due to the vesting of restricted stock units. The company withheld 7,397 shares to cover tax obligations, valuing these shares at $4.06 each, a transaction noted not to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 02:40
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Quartr
Direct company coverage
C4 Therapeutics (CCCC) Status Update Summary
C4 Therapeutics provided a status update on July 8, 2026, highlighting the prioritization of their drug Cemsidomide as a class-leading IKZF1/3 degrader for multiple myeloma. The drug shows promise with a projected peak revenue of $2.5–$4 billion in relapsed/refractory multiple my
- Tone
- Positive 76/100
- Event
- Earnings
- Published
- 09 Jul 2026 02:09
- Source
- Quartr
Market source
Direct company coverage
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
C4 Therapeutics, Inc. (CCCC) has seen a 2.65% increase in its stock price over the past week, outperforming the S&P 500 significantly over longer periods. The company holds a Zacks Momentum Style Score of A and a Zacks Rank of #2 (Buy), indicating strong short-term potential. Thi
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 03 Jul 2026 16:10
- Source
- Market source
Market source
Direct company coverage
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
C4 Therapeutics (CCCC) experienced a 16% gain over the past month, primarily due to positive phase 1 clinical trial data for its drug candidate Cemsidomide. The drug, targeting relapsed/refractory multiple myeloma, showed a 53% overall response rate in heavily pretreated patients
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 03 Jul 2026 13:10
- Source
- Market source
Finviz
Direct company coverage
CCCC - C4 Therapeutics Inc Options
This article provides an in-depth financial overview of C4 Therapeutics Inc. (CCCC), including its latest stock performance, key financial metrics, valuation ratios, and ownership data. It details the company's market capitalization, income, sales, earnings per share, and analyst
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 11:40
- Source
- Finviz
Finviz
Direct company coverage
CCCC - C4 Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filing information for C4 Therapeutics Inc (CCCC), including stock performance data, key financial metrics, and insider/institutional ownership details. As of July 2nd, the stock closed at $4.30 with a slight decrease, and the company has a ma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 23:39
- Source
- Finviz
Stock Titan
Direct company coverage
Director of C4 Therapeutics (NASDAQ: CCCC) receives 2,650-share stock award
Kenneth Carl Anderson, a director at C4 Therapeutics (NASDAQ: CCCC), received a stock award of 2,650 common shares on July 1, 2026. This award, valued at $4.34 per share, was issued in lieu of cash compensation for his board service, aligning with the company's Non-Employee Direc
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 19:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
Director at C4 Therapeutics (CCCC) takes 3,341 shares as fees
C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares, valued at $4.34 each, were issued under the company’s Non-Employee Director Compensation Policy as she elected stock in lieu of cash fees, increasing her direct
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 02 Jul 2026 19:40
- Source
- Stock Titan
TradingView
Direct company coverage
Price to book forward of C4 Therapeutics, Inc. – NASDAQ:CCCC
This article provides access to the "Price to book forward" financial metric for C4 Therapeutics, Inc. (NASDAQ: CCCC) through TradingView. It highlights that this data is part of the financials section for the company on the platform. The content is essentially a gateway to a spe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 05:39
- Source
- TradingView
StocksToTrade
Direct company coverage
CCCC Stock Climbs As C4 Therapeutics Posts Strong Phase 1 Myeloma Data
C4 Therapeutics (CCCC) stock rose by 8.62% following the release of positive updated Phase 1 data for its drug cemsidomide for relapsed/refractory multiple myeloma. The data showed a 53% overall response rate with durable and manageable safety, driving investor optimism. While th
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 30 Jun 2026 17:42
- Source
- StocksToTrade
marketscreener.com
Direct company coverage
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Benchmark
C4 Therapeutics, Inc. (NasdaqGS:CCCC) has been added to the Russell Small Cap Comp Value Benchmark, among various other Russell indexes. This inclusion highlights the company's growing presence in the financial markets. C4 Therapeutics is a clinical-stage biopharmaceutical compan
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 28 Jun 2026 22:10
- Source
- marketscreener.com
Stock Titan
Direct company coverage
C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike
C4 Therapeutics director Laura Bessen was granted 62,000 stock options at an exercise price of $4.25 per share, expiring on June 23, 2036. This is a compensation award, not an open-market trade, and the options will vest on the earlier of June 24, 2027, or the company’s next annu
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 08:41
- Source
- Stock Titan
Stock Titan
Direct company coverage
Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25
C4 Therapeutics Director Steven L. Hoerter was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will fully vest on the earlier of June 24, 2027, or the company’s next annual stockholder meeting, provided he remains o
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25
C4 Therapeutics director Owen Hughes was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. The options will fully vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided Hughes remains on th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:09
- Source
- Stock Titan
Moomoo
Direct company coverage
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for C4 Therapeutics, filed by Director Anderson Kenneth Carl. It details changes in his holdings of the company's securities, as required by the Securities and Exchange Commission. The filing e
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:42
- Source
- Moomoo
Investing.com Nigeria
Direct company coverage
Form 4 C4 Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing for C4 Therapeutics Inc, specifically for activity on June 26. The content is brief, primarily serving as a notification about the regulatory filing. It includes a market data table with various indices, commodities, bond
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 21:32
- Source
- Investing.com Nigeria
TradingView
Direct company coverage
C4 Therapeutics, Inc. Actuals & Estimates (NASDAQ:CCCC)
This article provides an overview of C4 Therapeutics, Inc. (NASDAQ: CCCC) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analysts' price targets, and information on earnings reports, revenue, net
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:39
- Source
- TradingView
Stock Titan
Direct company coverage
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity
C4 Therapeutics, Inc. director Kenneth Carl Anderson was granted 62,000 stock options to buy common stock at an exercise price of $4.25 per share. The options vest in full on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he continues to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options
C4 Therapeutics director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he remains on the Boa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:09
- Source
- Stock Titan
MSN
Direct company coverage
Are medical stocks lagging C4 Therapeutics (CCCC) this year?
This article from MSN discusses whether medical stocks are underperforming compared to C4 Therapeutics (CCCC) this year. The title suggests a focus on the relative stock performance within the medical sector.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 14:09
- Source
- MSN
Stock Titan
Direct company coverage
C4 Therapeutics (CCCC) director receives 62,000-share stock option award
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change
C4 Therapeutics, Inc. (NASDAQ: CCCC) stockholders approved the election of three Class III directors (Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar) to serve until the 2029 annual meeting. They also granted non-binding, advisory approval of named executive officer c
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 24 Jun 2026 20:10
- Source
- Stock Titan
Quartr
Direct company coverage
C4 Therapeutics (CCCC) AGM 2026 Summary
This article summarizes C4 Therapeutics' (CCCC) 2026 Annual General Meeting (AGM), held on June 24, 2026. Key agenda items included the election of Class III directors, an advisory vote on executive compensation, ratification of KPMG LLP as the auditor, and an amendment to the 20
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 19:11
- Source
- Quartr
TradingView
Direct company coverage
CCCC: All proposals, including director elections and stock plan amendment, passed by majority vote
C4 Therapeutics, Inc. (CCCC) held its Annual General Meeting (AGM) where all four proposed items passed by a majority vote. These proposals included the election of directors, executive compensation, auditor ratification, and a stock plan amendment. No shareholder questions were
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 13:09
- Source
- TradingView
TradingKey
Direct company coverage
C4 Therapeutics Inc (CCCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of C4 Therapeutics Inc (CCCC), detailing its current price momentum score of 8.84 and ranking within the Biotechnology & Medical Research industry. It identifies resistance at $4.67 and support at $3.51, suggesting suitability for range-
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 23 Jun 2026 09:40
- Source
- TradingKey
Seeking Alpha
Direct company coverage
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (NASDAQ:CCCC) 2026-06-20
C4 Therapeutics, Inc. (CCCC) presented a slideshow discussing the evolving landscape of multiple myeloma treatments. The presentation highlighted the significant role of IKZF1/3 degraders, including their proprietary drug, Cemsidomide. The company's insights focus on advancements
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 20 Jun 2026 19:13
- Source
- Seeking Alpha
The Globe and Mail
Direct company coverage
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards the healthcare sector, specifically highlighting C4 Therapeutics (CCCC) and Ocular Therapeutix (OCUL). Barclays analyst Etzer Darout maintained a Buy rating on C4 Therapeutics with a $7.00 price target, and the broader St
- Tone
- Positive 81/100
- Event
- Analyst action
- Published
- 19 Jun 2026 17:10
- Source
- The Globe and Mail